Paper Details

  1. Home
  2. Paper Details

Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.

Author: Bendek Del PreteGeorgina Emilia, BerriosRoxana Ramírez, FernándezIsolda, GiereIsabel, Mela OsorioMaría José, MoiraghiBeatriz, OsyckaMaría Victoria, PavlovskyCarolina, PavlovskyMiguel A, PérezMariel Ana, RivaMaría Elisa, Sackmann MassaFederico, SighelCarolina, TosinMaría Fernanda, VarelaAna Inés

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ponatinib is a third-generation tyrosine-kinase inhibitor (TKI) indicated in patients with chronic myeloid leukemia (CML) who are resistant or intolerant to ≥2 prior TKIs.
Paper Details　
Original Abstract of the Article :
Ponatinib is a third-generation tyrosine-kinase inhibitor (TKI), indicated in patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML), who are resistant or intolerant to ≥2 prior TKIs, patients for whom subsequent treatment with imatinib is not ap...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clml.2023.10.008

データ提供：米国国立医学図書館（NLM）

Ponatinib: A Long-Term Journey Through the Desert of Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) can be a long and arduous journey, a desert of uncertainty for patients facing this challenging disease. This study examines the long-term safety and efficacy of ponatinib, a third-generation tyrosine-kinase inhibitor (TKI), in patients with CML who are resistant or intolerant to other TKIs.

Ponatinib: A Potential Oasis in the Desert of CML Treatment

The study found that ponatinib showed sustained efficacy in controlling CML in patients with resistance or intolerance to other TKIs, providing a potential oasis of hope for those who have struggled to find effective treatment options. It's like finding a new source of water in the desert, offering a lifeline to those facing a difficult and challenging journey.

A Long-Term Solution for CML: The Potential of Ponatinib

This research highlights the potential of ponatinib as a long-term treatment option for CML, offering a new path towards managing this challenging disease. It's like finding a new caravan route through the desert, leading to a more manageable and sustainable solution for patients facing CML. While further research is needed to fully understand its long-term effects, this study provides encouraging evidence for the potential of ponatinib as a valuable treatment option for CML.

Dr.Camel's Conclusion

This study provides valuable insights into the long-term safety and efficacy of ponatinib for CML, offering a new source of hope for patients facing this challenging disease. It's like finding a new oasis in the desert, providing a lifeline to those facing a difficult and challenging journey.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-11-16
Further Info :

Pubmed ID

37973457

DOI: Digital Object Identifier

10.1016/j.clml.2023.10.008

Related Literature

Article Analysis
・Effects of ponatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.